Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.

15 However, this effect was only marginally statistically significant in unadjusted analyses ( P = .04), and most of the data were from trials in which sirolimus was used de novo and not following elective conversion as we did in our trial.

also in 1,110 other papers